Contact Congress about S. 1954: Biosimilar Red Tape Elimination Act

FDA-approved biosimilars would count as automatic substitutes for their brand-name biologic drugs. The bill removes a separate FDA approval step for that status, but it keeps older exclusivity rights in place until they end.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Biosimilar Red Tape Elimination Act is a Senate bill in committee. The latest recorded action: Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

Latest action on S. 1954: Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

Who this affects: This bill mainly affects people and organizations involved with biologic drugs and biosimilars. Patients may see more biosimilars offered as substitutes, depending on state pharmacy rules and insurance coverage. Drug makers would face a simpler FDA path for future biosimilars. Pharmacists, doctors, insurers, and health systems would need to adjust to a system with fewer separate labels.

Why this matters: This bill could change how quickly patients get biosimilars instead of higher-cost brand-name biologic drugs. Today, the FDA can approve a biosimilar without giving it the separate “interchangeable” label. That label can matter at the pharmacy. By making biosimilars interchangeable automatically, the bill could increase competition. But the real effect on prices and access is not guaranteed.

Key provisions in S. 1954

• Any biologic drug approved through the FDA biosimilar pathway would count as interchangeable with its brand-name reference drug. Timing rules still apply.
• The bill sets a transition date 60 days after it becomes law. On that date, most biosimilars already approved would become interchangeable.
• Companies that already earned first-interchangeable exclusivity would keep it. Their remaining protection would still run to the end.
• A new biosimilar may have to wait if another interchangeable biosimilar for the same brand-name drug still has exclusivity. It would become interchangeable after that protection ends.
• The bill removes the separate legal test and application steps for FDA interchangeability decisions under the biosimilar approval pathway.

How Modern Action helps you take action on S. 1954

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 1954

What is S. 1954?

FDA-approved biosimilars would count as automatic substitutes for their brand-name biologic drugs. The bill removes a separate FDA approval step for that status, but it keeps older exclusivity rights in place until they end.

How do I support or oppose S. 1954?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 1954?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain S. 1954 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.